Semaglutide and muscle loss: what SEMALEAN actually found

What did @drareginademiguel actually say?

This is genuinely difficult to assess. The transcript provided appears to be a machine-translation artifact or corrupted auto-caption from a Spanish-language video, and it contains no coherent medical claims. References to "superheroes," "belt," and "the government of America" have nothing to do with semaglutide or the SEMALEAN study. The caption, however, is specific: the creator references a real published study on semaglutide's impact on fat mass, lean mass, and muscle function in people with obesity, published in Diabetes, Obesity and Metabolism. The caption also frames the video as correcting misinformation, with the phrase "más ciencia, menos miedo" (more science, less fear). Since the transcript is unusable, this fact-check will assess the claims implied by the caption and the SEMALEAN study itself.

Does the science back this up?

The SEMALEAN study is real, and its findings are more reassuring than alarming, but not without important caveats that deserve honest discussion. The study found that semaglutide reduced fat mass substantially while preserving relative muscle function, but lean mass did decline in absolute terms.

The SEMALEAN study (Moriconi et al., 2023, Diabetes, Obesity and Metabolism) followed patients with obesity on semaglutide for 52 weeks. Fat mass dropped significantly, but lean mass also decreased by roughly 20-30% of total weight lost, a ratio consistent with other GLP-1 receptor agonist trials. Importantly, muscle function metrics, including handgrip strength and gait speed, did not worsen significantly. This distinction matters. Losing some lean mass during caloric restriction is expected; losing muscle function is the clinical concern. A broader meta-analysis by Ida et al. (2021, Diabetes Care) on GLP-1 agonists similarly showed lean mass reductions alongside fat mass reductions, with preserved or improved functional outcomes in most patients.

What did they get wrong (or right)?

Credit where it is due: framing the muscle loss conversation around the SEMALEAN study is the right move. Too many social media posts either catastrophize lean mass loss on GLP-1 drugs or dismiss the concern entirely. The "more science, less fear" framing is appropriate if the video accurately reflects what the study found.

The problem is we cannot verify what was actually said in this video because the transcript is incoherent. That is not a small caveat. If the video oversimplifies, cherry-picks the functional preservation finding while minimizing the absolute lean mass loss, that would be misleading in a different direction. Research by Wilding et al. (2021, NEJM) on semaglutide 2.4mg showed that roughly 38% of weight lost could be lean mass in some analyses, a figure that should be disclosed, not buried. On balance: the study citation appears legitimate, and the framing of the caption is responsible. But a full verdict requires a readable transcript.

What should you actually know?

Here is what the evidence actually supports, independent of this specific video. Semaglutide does cause some lean mass reduction during weight loss. This is not unique to GLP-1 drugs; it happens with any significant caloric deficit. The key question is whether muscle function, the ability to perform daily tasks, lift objects, maintain balance, is preserved. SEMALEAN and similar studies suggest it largely is, at least over 12 months.

Resistance training during semaglutide treatment appears to attenuate lean mass loss. A study by Sridharan et al. (2023, Obesity) found that patients who combined GLP-1 therapy with structured resistance exercise retained significantly more lean mass than those on pharmacotherapy alone. Protein intake also matters. These are practical, evidence-based interventions, not speculation. If you are on semaglutide and worried about muscle, talk to your prescribing clinician about protein targets and exercise programming. That conversation is far more productive than fear-based social media content in either direction.